{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:46:39Z","timestamp":1791492399191,"version":"4.3.4"},"reference-count":73,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000090","name":"DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-16-1-0245"],"award-info":[{"award-number":["W81XWH-16-1-0245"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n                    Bacteriophage-derived lysins are cell-wall-hydrolytic enzymes that represent a potential new class of antibacterial therapeutics in development to address burgeoning antimicrobial resistance. CF-301, the lead compound in this class, is in clinical development as an adjunctive treatment to potentially improve clinical cure rates of\n                    <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n                    bacteremia and infective endocarditis (IE) when used in addition to antibiotics.\n                  <\/jats:p>","DOI":"10.1128\/aac.02291-18","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T10:26:27Z","timestamp":1548239187000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":73,"title":["The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteriolysis"],"prefix":"10.1128","volume":"63","author":[{"given":"Chiara","family":"Indiani","sequence":"first","affiliation":[{"name":"ContraFect Corporation, Yonkers, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sauve","sequence":"additional","affiliation":[{"name":"ContraFect Corporation, Yonkers, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Raz","sequence":"additional","affiliation":[{"name":"Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Q.","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Cassino","sequence":"additional","affiliation":[{"name":"ContraFect Corporation, Yonkers, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Bayer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-573X","authenticated-orcid":false,"given":"Raymond","family":"Schuch","sequence":"additional","affiliation":[{"name":"ContraFect Corporation, Yonkers, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2016.05.006"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics7010017"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1206-1508"},{"key":"e_1_3_3_5_2","unstructured":"ClinicalTrials.gov. 2017. Safety efficacy and pharmacokinetics of cf-301 vs. placebo in addition to antibacterial therapy for treatment of S. aureus bacteremia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03163446."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit637"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02666-16"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-394438-2.00007-4"},{"key":"e_1_3_3_9_2","volume-title":"26th Eur Congr Clin Microbiol Infect Dis","author":"Cassino C","year":"2016","unstructured":"Cassino C, Murphy G, Boyle J, Rotolo J, Wittekind M. 2016. Results of the first in human study of lysin CF-301 evaluating the safety, tolerability and pharmacokinetic profile in healthy volunteers, poster EVLB62. 26th Eur Congr Clin Microbiol Infect Dis, Amsterdam, Netherlands."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01433-10"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21916"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00427-08"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm524"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq400"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3883-3891.2002"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(90)90067-6"},{"key":"e_1_3_3_18_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","author":"CLSI","year":"1999","unstructured":"CLSI. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781420014495.ch12"},{"key":"e_1_3_3_20_2","first-page":"5.12.1","volume-title":"Clinical microbiology procedures handbook","author":"Moody J","year":"2010","unstructured":"Moody J. 2010. Synergy testing: broth microdilution checkerboard and broth macrodilution methods, p 5.12.1\u20135.12.23. In Garcia LS (ed), Clinical microbiology procedures handbook, vol 2. ASM Press, Washington, DC."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780130405"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2004.04446.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0194-4"},{"key":"e_1_3_3_24_2","first-page":"431","article-title":"Blood serum concentrations of total proteins and main protein fractions in weaning rabbits experimentally infected with E. coli","volume":"159","author":"Georgieva TM","year":"2008","unstructured":"Georgieva TM, Penchev Georgiev I, Iliev Y, Petrov VS, Vachkov A, Kanelov IN, Tanev SI, Zapryanova D, Pavlov AI, Eckersall D. 2008. Blood serum concentrations of total proteins and main protein fractions in weaning rabbits experimentally infected with E. coli. Rev Med Vet 159:431\u2013436.","journal-title":"Rev Med Vet"},{"key":"e_1_3_3_25_2","first-page":"387","article-title":"Reference values for serum proteins of common laboratory rodent strains","volume":"48","author":"Zaias J","year":"2009","unstructured":"Zaias J, Mineau M, Cray C, Yoon D, Altman NH. 2009. Reference values for serum proteins of common laboratory rodent strains. J Am Assoc Lab Anim Sci 48:387\u2013390.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.372961"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15033580"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800622-JLR200"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)39899-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01625-09"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01877-16"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3791\/3863:e3863"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1714-1718.2003"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9072-1"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156131"},{"key":"e_1_3_3_37_2","first-page":"367","volume-title":"Antibiotics in laboratory medicine","author":"Craig WA","year":"1991","unstructured":"Craig WA, Suh B. 1991. Protein binding and the antimicrobial effects. Methods for determination of protein binding, p 367\u2013402. In Lorian V (ed), Antibiotics in laboratory medicine, 3rd ed. Williams and Wilkins, Baltimore, MD.","edition":"3"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1039\/C4MD00148F"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109943200"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0742-8413(95)02019-5"},{"key":"e_1_3_3_41_2","first-page":"382","article-title":"Comparison of drug binding sites on rat and human serum albumins using immobilized-protein stationary phases as a tool for the selection of suitable animal models in pharmacological studies","volume":"135","author":"Massolini G","year":"1996","unstructured":"Massolini G, De Lorenzi E, Ponci MC, Caccialanza G. 1996. Comparison of drug binding sites on rat and human serum albumins using immobilized-protein stationary phases as a tool for the selection of suitable animal models in pharmacological studies. Boll Chim Farm 135:382.","journal-title":"Boll Chim Farm"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.4049\/jimmunol.132.5.2582","article-title":"An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action","volume":"132","author":"Vaara M","year":"1984","unstructured":"Vaara M, Viljanen P, Vaara T, Makela PH. 1984. An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. J Immunol 132:2582\u20132589.","journal-title":"J Immunol"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041624"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.07.075"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M509691200"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2018.00060"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(99)01366-3"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5397-4"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02433"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01366-13"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aambs.2016.07.018"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.148171"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2016.2184"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00801-10"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7915.2011.00263.x"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00301-06"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02526-12"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00071-17"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03445-16"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2009.04.023"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604521103"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02518-09"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv007"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp126"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01175"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-016-0838-9"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155139"},{"key":"e_1_3_3_69_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6673-8_14"},{"key":"e_1_3_3_71_2","volume-title":"Pharmacokinetic indices driving antibacterial efficacy of cf-301\u2014a novel first-in-class lysin, abstr W-059","author":"Ghahramani P","year":"2016","unstructured":"Ghahramani P, Khariton T, Schuch R, Rotolo JA, Ramirez RA, Wittekind M. 2016. Pharmacokinetic indices driving antibacterial efficacy of cf-301\u2014a novel first-in-class lysin, abstr W-059. Am Conf Pharmacometrics, Bellevue, Washington."},{"key":"e_1_3_3_72_2","volume-title":"Interspecies scaling in pre-clinical population pharmacokinetics of CF-301, abstr W-039","author":"Chiu J","year":"2016","unstructured":"Chiu J, Khariton T, Ghahramani P, Lapinskas P, Cassino C, Carabeo T. 2016. Interspecies scaling in pre-clinical population pharmacokinetics of CF-301, abstr W-039. Am Conf Pharmacometrics, Bellevue, Washington."},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.8033-8038.2005"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw249"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02291-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02291-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:30:30Z","timestamp":1694561430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02291-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1128\/AAC.02291-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02291-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02291-18"}}